UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Alimentary pharmacology & therapeutics, 2015-01, Vol.41 (1), p.77-86

2015

Volltextzugriff (PDF)

The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review

Alimentary pharmacology & therapeutics, 2002-01, Vol.16 (1), p.51-60

2002

Volltextzugriff (PDF)

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

Gut, 2005-01, Vol.54 (1), p.91-96

2005

Volltextzugriff (PDF)

Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

Gut, 2006-11, Vol.55 (11), p.1561-1567

2006

Volltextzugriff (PDF)

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2008-09, Vol.28 (6), p.674-688

2008

Volltextzugriff (PDF)

Randomised clinical trial: herbal extract HMPL‐004 in active ulcerative colitis – a double‐blind comparison with sustained release mesalazine

Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (2), p.194-202

2011

Volltextzugriff (PDF)

Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival

Gut, 2000-03, Vol.46 (3), p.336-343

2000

Volltextzugriff (PDF)

Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers

Alimentary pharmacology & therapeutics, 2009-11, Vol.30 (9), p.930-936

2009

Volltextzugriff (PDF)

Crohn's disease in Olmsted County, Minnesota, 1940–1993: Incidence, prevalence, and survival

Gastroenterology (New York, N.Y. 1943), 1998-06, Vol.114 (6), p.1161-1168

1998

Volltextzugriff (PDF)

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

Gut, 2001-11, Vol.49 (5), p.665-670

2001

Volltextzugriff (PDF)

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

Gastroenterology (New York, N.Y. 1943), 1999-07, Vol.117 (1), p.49-57

1999

Volltextzugriff (PDF)

Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial

Alimentary pharmacology & therapeutics, 2005-02, Vol.21 (4), p.363-371

2005

Volltextzugriff (PDF)

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Gut, 2006-11, Vol.55 (11), p.1568-1574

2006

Volltextzugriff (PDF)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

Alimentary pharmacology & therapeutics, 2015-07, Vol.42 (2), p.188-202

2015

Volltextzugriff (PDF)

Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis – additional results from two controlled studies

Alimentary pharmacology & therapeutics, 2011-10, Vol.34 (7), p.747-756

2011

Volltextzugriff (PDF)

Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine

The American journal of gastroenterology, 1998-03, Vol.93 (3), p.442-448

1998

Volltextzugriff (PDF)

Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease

The American journal of gastroenterology, 1997-05, Vol.92 (5), p.876-879

SANDBORN, W. J

1997

Volltextzugriff (PDF)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (5), p.409-418

2015

Volltextzugriff (PDF)

Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (2), p.219-228

2018

Volltextzugriff (PDF)

Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease

Journal of Crohn's and colitis, 2013-04, Vol.7 (3), p.213-221

2013

Volltextzugriff (PDF)

Age at onset of inflammatory bowel disease and the risk of surgery for non‐neoplastic bowel disease

Alimentary pharmacology & therapeutics, 2007-06, Vol.25 (12), p.1435-1441

2007

Volltextzugriff (PDF)

Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis

Alimentary pharmacology & therapeutics, 2017-08, Vol.46 (3), p.292-302

2017

Volltextzugriff (PDF)

The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study

Gastroenterology (New York, N.Y. 1943), 2001-08, Vol.121 (2), p.255-260

2001

Volltextzugriff (PDF)

Acute major gastrointestinal hemorrhage in inflammatory bowel disease

Gastrointestinal endoscopy, 1999-02, Vol.49 (2), p.153-157

1999

Volltextzugriff (PDF)

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

Gastroenterology (New York, N.Y. 1943), 2004-01, Vol.126 (1), p.19-31

2004

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Aktive Filter

ThemaAdolescent

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(94)

Sprache

Englisch
(94)

Erscheinungsjahr

n.n

Thema

Humans
(94)
Adult
(90)
Life Sciences & Biomedicine
(89)
Science & Technology
(89)
Female
(86)
Male
(86)
Middle Aged
(83)
Gastroenterology & Hepatology
(82)
Aged
(73)
Biological And Medical Sciences
(45)
Medical Sciences
(45)
Aged, 80 And Over
(30)
Child
(30)
Gastroenterology. Liver. Pancreas. Abdomen
(30)
Other Diseases. Semiology
(27)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(27)
Treatment Outcome
(27)
Young Adult
(27)
Crohn Disease - Drug Therapy
(26)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

Randomised clinical trial: herbal extract HMPL‐004 in active ulcerative colitis – a double‐blind comparison with sustained release mesalazine

Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival

Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers

Crohn's disease in Olmsted County, Minnesota, 1940–1993: Incidence, prevalence, and survival

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis – additional results from two controlled studies

Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine

Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease

Age at onset of inflammatory bowel disease and the risk of surgery for non‐neoplastic bowel disease

Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis

The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study

Acute major gastrointestinal hemorrhage in inflammatory bowel disease

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

Aktive Filter

Suchergebnisse filtern